Results 51 to 60 of about 47,533 (300)
MiRNAs as novel adipokines : obesity-related circulating MiRNAs influence chemosensitivity in cancer patients [PDF]
, 2020 Adipose tissue is an endocrine organ, capable of regulating distant physiological processes in other tissues via the release of adipokines into the bloodstream.
Dewhurst, T +3 more
core +2 more sources
A Novel Combination Therapy for Human Oxaliplatin-resistant Colorectal Cancer Using Oxaliplatin and Coxsackievirus A11 [PDF]
Anticancer Research, 2018 Colorectal cancer (CRC) is a major cause of morbidity and mortality throughout the world. It is the third most common cancer worldwide and the fourth most common cause of cancer-related death. FOLFOX, a combination of leucovorin calcium, fluorouracil, and oxaliplatin, is the first-line chemotherapy for stage III and stage IV CRC. However, patients with
Beibei, Wang +12 more
openaire +2 more sources
A role for ceramide glycosylation in resistance to oxaliplatin in colorectal cancer
Experimental Cell Research, 2020 There is growing evidence to support a role for the ceramide-metabolizing enzyme, glucosylceramide synthase (GCS), in resistance to a variety of chemotherapeutic agents. Whether GCS contributes to oxaliplatin resistance in colorectal cancer (CRC) has not yet been determined.
James P, Madigan +7 more
openaire +3 more sources
Cell Death and Disease, 2022 Oxaliplatin is the main chemotherapy drug for gastric cancer (GC), but quite a few patients are resistant to oxaliplatin, which contributes to the poor prognosis of GC patients.
Xiaolong Tang +7 more
doaj +1 more source
Role of lncSLCO1C1 in gastric cancer progression and resistance to oxaliplatin therapy
Clinical and Translational Medicine, 2022 AbstractBackgroundGastric carcinoma (GC) is one of the most deadly diseases due to tumour metastasis and resistance to therapy. Understanding the molecular mechanism of tumour progression and drug resistance will improve therapeutic efficacy and develop novel intervention strategies.MethodsDifferentially expressed long non‐coding RNAs (lncRNAs) in ...
Yu‐Feng Xiao +9 more
openaire +3 more sources
UCN-01 enhances cytotoxicity of irinotecan in colorectal cancer stem-like cells by impairing DNA damage response [PDF]
, 2016 Colorectal cancer (CRC) is one of the most common and lethal cancers worldwide. Despite recent progress, the prognosis of advanced stage CRC remains poor, mainly because of cancer recurrence and metastasis.
Biffoni, Mauro +9 more
core +1 more source
Therapeutic potential of the phosphino Cu(I) complex (HydroCuP) in the treatment of solid tumors [PDF]
, 2017 [Cu(thp)4][PF6] (HydroCuP) is a phosphino copper(I) complex highly soluble and stable in physiological media that has been developed as a possible viable alternative to platinum-based drugs for anticancer therapy.
Ceresa, Cecilia +8 more
core +3 more sources
Immunotherapy, Inflammation and Colorectal Cancer. [PDF]
, 2020 Colorectal cancer (CRC) is the third most common cancer type, and third highest in mortality rates among cancer-related deaths in the United States.
Karin, Michael +3 more
core +1 more source
Oncotarget, 2017 Erythropoietin-producing hepatocellular receptor A2 (EphA2) is upregulated in gastric cancer tissues and cells, which is accompanied by epithelial-mesenchymal transition (EMT). The current study was designed to establish the oxaliplatin-resistant human gastric cancer cell line SGC-7901/L-OHP, to determine if EMT in these cells could be reversed, and to
Wen, Qiaocheng +6 more
openaire +2 more sources
HNF1A regulates oxaliplatin resistance in pancreatic cancer by targeting 53BP1
International Journal of Oncology, 2023 DNA double‑strand break repair is critically involved in oxaliplatin resistance in pancreatic ductal adenocarcinoma (PDAC). Hepatocyte nuclear factor 1 homeobox A (HNF1A) has received increased attention regarding its role in cancer progression. The present study explored the role of HNF1A in oxaliplatin resistance in PDAC.
Xia, Renpeng +8 more
openaire +2 more sources